Key Points
- CFO Emily Luisa Hill sold 9,256 Replimune shares for approximately $132,176 at an average price of $14.28. The filing said the sale covered tax-withholding obligations tied to vested equity awards; she retained 215,852 shares.
- Replimune reported a quarterly loss of $0.72 per share, missing analysts’ $0.69-loss estimate. The stock opened at $14.81, near its 52-week high of $15.70, despite reporting a negative P/E ratio.
- Analyst sentiment remains generally positive, with a consensus rating of “Moderate Buy” and price targets as high as $20, although the consensus target is $11.86. Institutional investors own approximately 92.53% of the company’s shares.
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) CFO Emily Luisa Hill sold 9,256 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the transaction, the chief financial officer owned 215,852 shares in the company, valued at $3,082,366.56. The trade was a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Emily Luisa Hill also recently made the following trade(s):
- On Monday, August 10th, Emily Luisa Hill sold 11,448 shares of Replimune Group stock. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56.
Replimune Group Stock Down 4.9%
REPL stock opened at $14.81 on Thursday. The stock's 50 day simple moving average is $11.02 and its 200 day simple moving average is $7.95. The company has a market cap of $1.39 billion, a P/E ratio of -4.70 and a beta of 0.88. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.79 and a current ratio of 5.23. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $15.70.
Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). On average, research analysts expect that Replimune Group, Inc. will post -2.78 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have issued reports on REPL shares. Cantor Fitzgerald restated an "overweight" rating on shares of Replimune Group in a research note on Wednesday, August 12th. Leerink Partners upgraded Replimune Group from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $11.00 to $17.00 in a research note on Tuesday, August 4th. Wolfe Research raised shares of Replimune Group to an "outperform" rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $17.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Replimune Group from a "strong sell" rating to a "sell" rating in a report on Saturday, May 23rd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $11.86.
Check Out Our Latest Analysis on REPL
Trending Headlines about Replimune Group
Here are the key news stories impacting Replimune Group this week:
- Neutral Sentiment: Replimune announced inducement equity awards for Chief Commercial Officer Michelle DiNapoli under Nasdaq Listing Rule 5635(c)(4). The grants are intended to support employee recruitment and retention, but will modestly increase potential share dilution. Replimune Announces Inducement Grants
- Neutral Sentiment: CFO Emily Luisa Hill sold 9,256 shares for approximately $132,176 at an average price of $14.28. The filing states the sale was made to cover tax-withholding obligations tied to vested equity awards; she continues to own 215,852 shares, reducing the signal of discretionary insider selling. SEC Insider Transaction Filing
- Negative Sentiment: Several law firms publicized the securities class action and reminded investors of the October 5, 2026 deadline to seek lead-plaintiff status. The complaints allege Replimune’s filings did not adequately disclose that FDA concerns about the RP1 study design remained unresolved. Although the allegations have not been proven, the legal uncertainty creates an overhang and could increase potential costs or liabilities. Replimune Securities Fraud Lawsuit Deadline Alert
Hedge Funds Weigh In On Replimune Group
Several hedge funds have recently bought and sold shares of the company. Hsbc Holdings PLC bought a new stake in Replimune Group during the second quarter valued at $1,035,000. Wellington Management Group LLP increased its stake in Replimune Group by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 215,302 shares of the company's stock worth $2,383,000 after acquiring an additional 17,724 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in Replimune Group in the 2nd quarter worth about $5,485,000. Bank of America Corp DE purchased a new stake in shares of Replimune Group in the 2nd quarter valued at about $3,646,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Replimune Group in the 2nd quarter valued at about $7,260,000. Hedge funds and other institutional investors own 92.53% of the company's stock.
About Replimune Group
(
Get Free Report)
Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.
Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
